CLINICAL EXPERIENCE AND USE OF VIGABATRIN IN PATIENTS WITH INFANTILE SPASMS

婴儿痉挛症患者氨己烯酸的临床经验和使用

• 批准号: 6113653
• 负责人: WENDY G. MITCHELL
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113653
• 关键词: anticonvulsants; brain disorder chemotherapy; child (0-11); clinical research; drug screening /evaluation; epilepsy; generalized seizures; human subject; human therapy evaluation; infant human (0-1 year); spasm

Infantile spasms are a severe type of seizures which occur in infants. The outlook for a child with infantile spasms is poor: most are developmentally disabled, and a majority continue to have severe epilepsy. ACTH is the most commonly used treatment for infantile spasms and is successful at least temporarily in about 70% However, adverse effects are significant. Conventional anticonvulsants are only occasionally effective. Vigabatrin, a new anticonvulsant is being evaluated for safety and efficacy in treating infantile spasms.

婴儿痉挛是发生在婴儿身上的一种严重的癫痫发作。患有婴儿痉挛的儿童的前景很差：大多数是发育障碍，大多数仍然患有严重的癫痫。促肾上腺皮质激素是婴儿痉挛最常用的治疗方法，至少有70%的患者暂时成功。传统的抗惊厥药只是偶尔有效。Vigabatrin，一种新的抗惊厥药，正在评估其治疗婴儿痉挛的安全性和有效性。